| 1 |
patient-derived xenografts
(492 times)
|
Neoplasms
(204 times)
|
CRC (23 times)
TNBC (21 times)
NSCLC (16 times)
|
2012 Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients.
|
| 2 |
patient-derived tumor xenografts
(38 times)
|
Neoplasms
(19 times)
|
BC (3 times)
CRC (2 times)
CSCs (2 times)
|
2014 Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.
|
| 3 |
patient-derived prostate cancer xenografts
(4 times)
|
Urology
(2 times)
|
EBV (1 time)
hOTEC (1 time)
PEG (1 time)
|
2015 Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.
|
| 4 |
panel of sarcoma cell lines and sarcoma tumor xenografts
(1 time)
|
Neoplasms
(1 time)
|
---
|
2015 Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
|
| 5 |
patient derived ovarian xenografts
(1 time)
|
Neoplasms
(1 time)
|
BEV (1 time)
MEK (1 time)
PTX (1 time)
|
2017 Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
|
| 6 |
patient tumor tissue derived xenografts
(1 time)
|
Medicine
(1 time)
|
GEMMs (1 time)
|
2016 Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
|
| 7 |
patient-derived IDH1/2-mutant AML/ MDS xeno-grafts
(1 time)
|
Hematology
(1 time)
|
AML (1 time)
HR (1 time)
MDS (1 time)
|
2022 In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
|
| 8 |
Patient-derived organoids and xenografts
(1 time)
|
Neoplasms
(1 time)
|
---
|
2018 Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response.
|
| 9 |
patient-derived orthotopic xenografts
(1 time)
|
Neoplasms
(1 time)
|
---
|
2016 Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.
|
| 10 |
patient-derived primary tumour xenografts
(1 time)
|
Neoplasms
(1 time)
|
CSCs (1 time)
|
2017 Metformin targets gastric cancer stem cells.
|
| 11 |
patient-derived xenolines
(1 time)
|
Biochemistry
(1 time)
|
GBMs (1 time)
GSCs (1 time)
IFNs (1 time)
|
2017 The effects of type I interferon on glioblastoma cancer stem cells.
|
| 12 |
plain decellularized xenografts
(1 time)
|
Transplantation
(1 time)
|
---
|
2006 In vivo recellularization of plain decellularized xenografts with specific cell characterization in the systemic circulation: histological and immunohistochemical study.
|
A Search Service for Abbreviation / Long Form